Merck’s Covid-19 pill Molnupiravir only 30% effective in final analysis

The pharmaceutical company Merck said on Friday that in a final analysis of a clinical trial, its antiviral pill molnupiravir reduced the risk of hospitalization and death among high-risk Covid patients by 30 percent, down from an earlier estimate of 50 percent....More...